We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 378.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/6/2020 13:04 | "RNS 600 labs have it and can produce 10k tests per month 6m per month at say £5 a test is £30m revenue"... a pretty obvious limitation to this calculation is that these systems are already being used to diagnose other illnesses - what spare capacity is left we do not know. | wigwammer | |
18/6/2020 09:04 | Bought in this morning after watching for a few days - a CE Marked quantitative test is big news... | 74tom | |
17/6/2020 20:16 | Agree, Hedgehog. Don't think people bothered to read the results: "In the short term we will also focus on commercialising opportunities arising from Increased levels of SARS-CoV2 antibody testing using a range of automated and manual test kits which we expect to launch during Q1 FY2021." "In addition, we have agreed commercial terms with a UK based specialist medical diagnostics company to produce components of their COVID-19 ELISA manual assay." ODX ?! Omega diagnostics. | 2toptrader | |
17/6/2020 16:04 | IDH is a former 20-bagger. And it has plenty of facilities and cash to help address the COVID-19 testing shortage. This could fuel another great period of share price performance. IDH's current market cap. is £80.6M. at 280p, of which over a third is covered by its cash of about £28M. And this is a nice market cap. for a growing business to achieve a stellar rating from. Because tracker funds are forced to buy in as the share price and market cap. rise. This dynamic helped to fuel IDH's stellar rise to over £12 a share about a decade ago. | hedgehog 100 | |
17/6/2020 14:25 | It was a 'fake drop' early this morning: virtually all buys today, and at 280p the share price is now up on the day. IDH has a lot going on regarding the massive COVID-19 opportunity, and the company promises to update the market re. any significant developments: 17/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Final Results " ... 7. Outlook ... We are working to manufacture and commercialise CLIA and ELISA tests to detect SARS-CoV-2 antibodies, combining our resources and capabilities with partners who complement our skill set with their virology know-how. A summary of the opportunities we are working on is set out in Jaap's CEO report, and we will update the market via RNS if there is any significant news in this area. ... Opportunities We are currently in negotiations with a number of partners to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats. We are currently working to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats, combining our resources and capabilities with partners who have knowledge in virology and infectious diseases. Our development partner, Technogenetics, has developed a COVID-19 IgG assay to detect SARS-CoV-2 antibodies. This quantitative automated assay which runs on the IDS-iSYS analyser, should be available for sale by IDS before the end of June, in Europe and distribution regions whose regulatory regime is based on the CE-mark. In addition, we have agreed commercial terms with a UK based specialist medical diagnostics company to produce components of their COVID-19 ELISA manual assay. Finally, we are working with a number of partners with expertise in virology and immunology to provide a route to market for ELISA-based COVID-19 assays, utilising our direct sales organisation as well as our extensive distribution network. ..." I think that we can expect some very exciting IDH newsflow over the summer, which should help drive the share price to much higher levels. | hedgehog 100 | |
17/6/2020 07:38 | Nice 7.3% drop on no volume. Hmmmm!!!!Hopefully that should settle the naysayers on mm manipulation | mw16 | |
17/6/2020 06:26 | "We are currently working to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats, combining our resources and capabilities with partners who have knowledge in virology and infectious diseases. Our development partner, Technogenetics, has developed a COVID-19 IgG assay to detect SARS-CoV-2 antibodies. This quantitative automated assay which runs on the IDS-iSYS analyser, should be available for sale by IDS before the end of June, in Europe and distribution regions whose regulatory regime is based on the CE-mark. In addition, we have agreed commercial terms with a UK based specialist medical diagnostics company to produce components of their COVID-19 ELISA manual assay. Finally, we are working with a number of partners with expertise in virology and immunology to provide a route to market for ELISA-based COVID-19 assays, utilising our direct sales organisation as well as our extensive distribution network." MC £80 mil, cash £27 mil, profitable and paying a dividend. What the hell is wrong with this markets ?! | 2toptrader | |
15/6/2020 22:42 | Seller cleared. Could be an interesting week | bob1995 | |
15/6/2020 01:18 | We achieved sales or placements of 93 (FY19: 84) analysers in our direct and distribution businesses, our strongest performance since 2012 | letmepass | |
13/6/2020 18:09 | Ah I see the twitter story.. old news, different assays | wigwammer | |
13/6/2020 18:08 | Sorry colin - I'm not sure what news you are referring to? | wigwammer | |
13/6/2020 18:05 | Dpl - with the best will in the world, ODX has to split Covid revenues 5 ways, it has minimal existing sales, minimal cash and a speculative valuation at £90m market cap. Perhaps there will be a rally if/when they get something closer to market, but it's not exactly a hidden gem! | wigwammer | |
13/6/2020 14:36 | swerves dont be stupid who rns it first it s the other way round | colin12345678 | |
13/6/2020 13:43 | ODX making the antibody test for IDH? | swerves1 | |
13/6/2020 13:18 | wigwammer bang on the money see on twitter its linked with ODX so game on monday | colin12345678 | |
13/6/2020 10:24 | With a lab test - the result can only have come from you. A doctor or nurse will certify this is the case. The data will have greater accuracy, and will be quantitative - giving the authorities more precise and accurate data with a verified provenance. It's all about the data. | wigwammer | |
13/6/2020 10:22 | Yes but these things have been done in a rush, does it make sense? The authorities need to get this right because precise, accurate data with provenance is going to be invaluable. So you?ve gone to boots, bought a test, tested positive (according to a fairly arbitrary hurdle). After that - things get difficult, don?t they.. | wigwammer | |
13/6/2020 09:41 | Provenance | wigwammer | |
13/6/2020 09:38 | Still not sure a yes/no home test is going to be the preferred route. Better to have a quantitative lab test where the authorities can have confidence in the preciseness, quality and providence of the data being collected. Perhaps the home yes/no test will be a first step. | wigwammer | |
12/6/2020 15:32 | and they give you a passport to go back to work its open to all sorts of skullduggery a home test | colin12345678 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions